Table 6.
Group | SOD (U/mg prot) | CAT (U/mg prot) | GSH-Px (U/mg prot) | GR (U/g prot) | GST (nmol/min/mg prot) |
---|---|---|---|---|---|
NC | 164.9 ± 12.67 | 32.65 ± 3.05 | 27.51 ± 1.85 | 31.43 ± 1.65 | 43.54 ± 4.21 |
MC (CCl4) | 83.2 ± 5.09 b | 16.93 ± 1.52 b | 10.73 ± 1.05 b | 13.16 ± 1.25 b | 21.34 ± 1.85 b |
CCl4 + LE (100 mg/kg b.w.) | 103.9 ± 8.01 d | 20.11 ± 1.67 c | 15.75 ± 1.93 c | 21.85 ± 1.21 d | 31.54 ± 2.86 d |
CCl4 + LE (150 mg/kg b.w.) | 114.5 ± 8.23 d | 22.07 ± 1.88 d | 19.32 ± 1.43 d | 22.43 ± 1.07 d | 34.21 ± 2.53 d |
CCl4 + LE (300 mg/kg b.w.) | 159.2 ± 11.72 d | 30.57 ± 2.53 d | 26.19 ± 1.97 d | 30.41 ± 2.63 d | 41.83 ± 3.92 d |
CCl4 + bifendate | 142.1 ± 10.61 d | 27.58 ± 2.22 d | 24.62 ± 2.31 d | 29.42 ± 1.84 d | 36.1 ± 4.17 d |
P < 0.01, compared with NC group;
P < 0.05;
P < 0.01, compared with CCl4-treated group; NC: normal control.